Clinical trial
Zosuquidar in Combination With Daunorubicin and Cytarabine in Patients Ages…
NCT00129168 · Kanisa Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00129168 |
|---|---|
| Title | Zosuquidar in Combination With Daunorubicin and Cytarabine in Patients Ages 55-75 With Newly Diagnosed Acute Myeloid Leukemia (AML) |
| Official title | An Open-Label, Phase I/II, Multicenter Dose Escalation Study of Zosuquidar, Daunorubicin, and Cytarabine in Patients Ages 55-75 With Newly Diagnosed Acute Myeloid Leukemia |
| Lead sponsor | Kanisa Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia, Myeloid |
| Intervention type | Drug |
| Interventions | Zosuquidar, Daunorubicin, Cytarabine |
| Enrollment | 100 |
| Start date | Aug 1, 2005 |
| Primary completion | Mar 1, 2008 |
| Completion | Mar 1, 2008 |
| First posted | Aug 11, 2005 |
| Last update posted | Apr 1, 2008 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: